HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation

BACKGROUND: Concurrent cisplatin radiotherapy (CCRT) is a current standard-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT is frequently ineffective in patients with advanced disease. It has previously been shown that HSP90 inhibitors act as radiosensitizers...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: McLaughlin, Martin, Barker, Holly E., Khan, Aadil A., Pedersen, Malin, Dillon, Magnus, Mansfield, David C., Patel, Radhika, Kyula, Joan N., Bhide, Shreerang A., Newbold, Kate L., Nutting, Christopher M., Harrington, Kevin J.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5282703/
https://ncbi.nlm.nih.gov/pubmed/28143445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3084-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados